









市場
/
株式
/
nasdaq-eypt
/

EyePoint Pharmaceuticals Inc

EYPT

18.260USD

-0.120-0.65%

終値 12/24, 13:00（ET）15分遅れの株価

1.27B時価総額

損失額直近12ヶ月PER



EyePoint Pharmaceuticals Inc

18.260

-0.120-0.65%

概要企業名金融分析

概要

企業名

金融

分析

詳細情報 EyePoint Pharmaceuticals Inc 企業名

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.

EyePoint Pharmaceuticals Incの企業情報



企業コードEYPT

会社名EyePoint Pharmaceuticals Inc

上場日Jan 27, 2005

最高経営責任者「CEO」Duker (Jay S)

従業員数165

証券種類Ordinary Share

決算期末Jan 27

本社所在地480 Pleasant Street, Suite C400

都市WATERTOWN

証券取引所NASDAQ OMX - NASDAQ BASIC

国United States of America

郵便番号02472

電話番号16179265000

ウェブサイトhttps://eyepointpharma.com/

企業コードEYPT

上場日Jan 27, 2005

最高経営責任者「CEO」Duker (Jay S)

EyePoint Pharmaceuticals Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

565.46K

-1.62%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

39.06K

-6.51%

Dr. Reginald J Sanders, M.D.

Non-Executive Independent Director

Mr. Fred Hassan

Non-Executive Independent Director

Mr. Stern

Investor Relations

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

565.46K

-1.62%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2024

FY2023

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

事業別USD

会社名

収益

比率

YUTIQ

3.10M

7.16%

地域別USD

会社名

収益

比率

United States

42.05M

97.17%

China

1.12M

2.60%

United Kingdom

100.00K

0.23%

事業別

地域別

事業別USD

会社名

収益

比率

YUTIQ

3.10M

7.16%

株主

更新時刻: Mon, Nov 17

株主統計

種類

株主統計

比率

Cormorant Asset Management, LP

9.98%

Suvretta Capital Management, LLC

7.48%

Adage Capital Management, L.P.

6.72%

BlackRock Institutional Trust Company, N.A.

5.17%

Franklin Advisers, Inc.

5.00%

他の

65.65%

株主統計

比率

Cormorant Asset Management, LP

9.98%

Suvretta Capital Management, LLC

7.48%

Adage Capital Management, L.P.

6.72%

BlackRock Institutional Trust Company, N.A.

5.17%

Franklin Advisers, Inc.

5.00%

他の

65.65%

種類

株主統計

比率

Hedge Fund

32.77%

Investment Advisor

23.90%

Investment Advisor/Hedge Fund

19.30%

Research Firm

4.43%

Private Equity

3.39%

Individual Investor

2.73%

Venture Capital

2.58%

Bank and Trust

1.06%

Pension Fund

0.13%

他の

9.71%

機関投資家保有株



更新時刻: Mon, Dec 8

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q4

363

69.86M

126.07%

2025Q3

373

69.94M

127.01%

+1.23K

2025Q2

381

69.95M

127.71%

-5.27M

2025Q1

371

75.32M

126.89%

-11.89M

2024Q4

359

75.24M

109.81%

+11.20M

2024Q3

343

59.71M

126.62%

+193.11K

2024Q2

330

60.06M

120.79%

+1.75M

2024Q1

313

56.72M

108.78%

+2.51M

2023Q4

268

50.21M

76.86%

+16.41M

2023Q3

224

33.81M

98.97%

+2.98M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

Cormorant Asset Management, LP

8.32M

12.08%

Jun 30, 2025

Suvretta Capital Management, LLC

6.80M

9.87%

Jun 30, 2025

Adage Capital Management, L.P.

6.80M

9.87%

+600.00K

+9.68%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.60M

6.67%

-346.31K

-7.00%

Jun 30, 2025

Franklin Advisers, Inc.

4.27M

6.19%

+148.48K

+3.60%

Jun 30, 2025

The Vanguard Group, Inc.

3.80M

5.52%

-15.98K

-0.42%

Jun 30, 2025

Federated Hermes Global Investment Management Corp.

3.58M

5.2%

-128.17K

-3.45%

Jun 30, 2025

TCG Crossover Management, LLC

3.57M

5.18%

Jun 30, 2025

Citadel Advisors LLC

2.34M

3.4%

+58.12K

+2.54%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

日付

種類

比率

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

よくある質問

EyePoint Pharmaceuticals Incの上位5名の株主は誰ですか？



EyePoint Pharmaceuticals Incの上位5名の株主は以下のとおりです。
Cormorant Asset Management, LPは8.32M株を保有しており、これは全体の12.08%に相当します。
Suvretta Capital Management, LLCは6.80M株を保有しており、これは全体の9.87%に相当します。
Adage Capital Management, L.P.は6.80M株を保有しており、これは全体の9.87%に相当します。
BlackRock Institutional Trust Company, N.A.は4.60M株を保有しており、これは全体の6.67%に相当します。
Franklin Advisers, Inc.は4.27M株を保有しており、これは全体の6.19%に相当します。